|Angiocrine Bioscience Inc., of San Diego||AB-205||Human engineered cord endothelial cells||Organ vascular niche injuries in patients with Hodgkin lymphoma and non-Hodgkin lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation||FDA granted regenerative medicine advanced therapy designation|
|Bioxcel Inc., of New Haven, Conn.||BXCL-501||Sublingual thin film formulation of dexmedetomidine||Agitation in patients with schizophrenia and bipolar disorders||After completing the pre-NDA meeting with the FDA, the company believes its regulatory data package will be sufficient for submission of the NDA; plans to complete rolling submission in the first quarter of 2021|
|Gyroscope Therapeutics Ltd., of London||GT-005||Complement factor stimulator||Geographic atrophy in patients with variants in their complement genes||FDA granted fast track designation|
|Inventiva SA, of Daix, France||Lanifibranor||Activates the 3 peroxisome proliferator‑activated receptor isoforms||Nonalcoholic steatohepatitis||Completed end-of-phase-II meeting with the FDA|
|Sebela Pharmaceuticals Inc., of Braintree, Mass.||Sutab||Sulfate-based tablet||Bowel prep for colonoscopies||FDA approved the drug|
|Sorrento Therapeutics Inc., of San Diego||Covi-Drops (STI-2099)||Neutralizing antibody against SARS-CoV-2||Mild COVID-19||Filed an IND with the FDA|
|Surface Oncology Inc., of Cambridge, Mass.||SRF-388||Monoclonal antibody targeting IL-27||Hepatocellular carcinoma after standard therapies||FDA granted fast track designation|
For more information about individual companies and/or products, see Cortellis.